Update on biomarkers in development of anti-angiogenic drugs in gastric cancer

Anticancer Research

Volumn 36, Issue 3, 2016, Pages 1111-1118

  Jia, Shuqin ^a,b   Cai, Jun ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Anti angiogenic treatment; Biomarker development; Gastric cancer; Review; VEGF inhibitors

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CD31 ANTIGEN; CEDIRANIB; CHEMOKINE RECEPTOR CXCR1; FLUOROURACIL; FOLINIC ACID; LIPOCORTIN 2; MICRORNA; MICRORNA 160A; MICRORNA 17 5P; MICRORNA 21; MICRORNA 378; MICRORNA 451; MICRORNA 486; NEUROPILIN 1; OXALIPLATIN; PACLITAXEL; PLACENTAL GROWTH FACTOR; RAMUCIRUMAB; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADVANCED CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CIRCULATING TUMOR CELL; CONFERENCE PAPER; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENERGY METABOLISM; GENOTYPE; HUMAN; HYPERTENSION; MOLECULAR IMAGING; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; STOMACH CANCER; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; ECONOMICS; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE; STOMACH NEOPLASMS; TUMOR EMBOLISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PRECISION MEDICINE; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84991688622     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. American Cancer Society: Cancer facts and figures. Altanta, GA, USA: American Cancer Society; 2013. Last accessed June 8, 2014.
2. Takahashi T, Saikawa Y and Kitagawa Y: Gastric cancer: current status of diagnosis and treatment. Cancers 5: 48-63, 2013.
3. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M and Kang YK: Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976, 2011.
4. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N and Maruyama M: Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 29: 550-555, 1999.
5. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A and Group RS: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase III trial. Lancet Oncol 15: 1224-1235, 2014.
6. Sander M, Chavoshan B and Victor RG: A large blood pressureraising effect of nitric oxide synthase inhibition in humans. Hypertension 33: 937-942, 1999.
7. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J and Investigators RT: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase III trial. Lancet 383: 31-39, 2014.
8. Duda DG: Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol 2012: 1-11, 2012.
9. de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N, Escudier B, Van Cutsem E, Carmeliet P, Scherer SJ, Pallaud C and Lambrechts D: Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 17: 909-920, 2014.
10. Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R, Castells A and Pera M: High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 96: 1443-1451, 2009.
11. Murukesh N, Dive C and Jayson GC: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 102: 8-18, 2010.
12. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL and Alberts DS: Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16: 5320-5328, 2010.
13. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK and Kelsen DP: Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201-5206, 2006.
14. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ and Shah MA: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30: 2119-2127, 2012.
15. Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T and Ohta T: VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. OncoTargets & Ther 6: 1445-1451, 2013.
16. Wang X, Chen X, Fang J and Yang C: Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis and silencing of both is effective to inhibit cancer growth. Int J ClinExp Pathol 6: 586-597, 2013.
17. Angelescu C, Burada F, Ioana M, Angelescu R, Moraru E, Riza A, Marchian S, Mixich F, Cruce M and Saftoiu A: VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers. Clin & Trans Oncol 15: 313-320, 2013.
18. Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, Sasaki T and Miura M: Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol 10: 318-327, 2005.
19. Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ and Lee PH: The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213: 73-82, 2004.
20. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT and Sorensen AG: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338, 2009.
21. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
22. Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, Kondo Y, Gorrin-Rivas MJ, Furumoto K, Kaneda Y and Imamura M: Soluble FLT1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 7: 1027-1033, 2000.
23. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T and Bottaro DP: Phase II study evaluating two dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PloS one 8: e54014, 2013.
24. Ha X, Zhao M, Zhao H, Peng J, Deng Z, Dong J, Yang X, Zhao Y and Ju J: Identification and clinical significance of circulating endothelial progenitor cells in gastric cancer. Biomarkers 18: 487-492, 2013.
25. Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, Park KH, Noh SH, Roh JK and Chung HC: Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett 288: 124-132, 2010.
26. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M: Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26: 4899-4905, 2008.
27. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M and Lauwers GY: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23: 8136-8139, 2005.
28. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD and Heymach JV: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13: 2643-2650, 2007.
29. Yu S, Yu Y, Zhao N, Cui J, Li W and Liu T: C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PloS one 8: e79137, 2013.
30. Tian Zhang RB, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, Herbert Hurwitz, Mariano A. Garcia-Blanco andrew J. Armstrong; Duke University Medical Center, Durham, NC; Veridex LLC, Huntingdon Valley, PA: Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies. In: 2015 Gastrointestinal Cancers Symposium: Janssen Research and Development, Spring House, PA; Duke University, Durham, NC, 2015.
31. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T, Kawaguchi T, Hirashima S, Fujiwara H, Okamoto K and Otsuji E: Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer 106: 740-747, 2012.
32. Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, Yuasa Y, Kang D, Kim YS and You WC: Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PloS one 7: e33608, 2012.
33. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K and Otsuji E: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102: 1174-1179, 2010.
34. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY and Zhu ZG: MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol 108: 89-92, 2013.
35. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Diaz P, Lorenzo-Patino MJ, Haz M, Santamarina I, Blanco M, Fernandez-Tajes J, Quindos M, Carral A, Figueroa A, Anton-Aparicio LM and Calvo L: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Trans Med 10: 186, 2012.
36. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
37. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
38. Fernandes J, Michel V, Camorlinga-Ponce M, Gomez A, Maldonado C, De Reuse H, Torres J and Touati E: Circulating mitochondrial DNA level, a noninvasive biomarker for the early detection of gastric cancer. Cancer Epidemiol, Biomarkers Prev: 23: 2430-2438, 2014.
39. Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437, 2011.
40. Kim K, Shin DG, Park MK, Baik SH, Kim TH, Kim S and Lee S: Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res 86: 136-142, 2014.
41. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, Takayama T, Uchida H, Kamada K, Naito A, Hirao S and Nakajima Y: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21: 1339-1345, 2001.
42. Tas F, Tilgen Yasasever C, Karabulut S, Tastekin D and Duranyildiz D: Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables. Biomed Pharmacother 69: 237-241, 2015.
43. Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Hwang JA, Hong SH, Graves CA, Camphausen K, Kim HJ and Lee YS: The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC cancer 13: 43, 2013.
44. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F and Roselli M: Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan and bevacizumab. Int J Colorectal Dis 26: 143-151, 2011.
45. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L and Lenz HJ: Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14: 7554-7563, 2008.
46. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD and Ecog: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26: 4672-4678, 2008.
47. Chen J, Michan S, Juan AM, Hurst CG, Hatton CJ, Pei DT, Joyal JS, Evans LP, Cui Z, Stahl A, Sapieha P, Sinclair DA and Smith LE: Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy. Angiogenesis 16: 985-992, 2013.
48. Choi I, Lee YS, Chung HK, Choi D, Ecoiffier T, Lee HN, Kim KE, Lee S, Park EK, Maeng YS, Kim NY, Ladner RD, Petasis NA, Koh CJ, Chen L, Lenz HJ and Hong YK: Interleukin-8 reduces post-surgical lymphedema formation by promoting lymphatic vessel regeneration. Angiogenesis 16: 29-44, 2013.
49. Lastraioli E, Romoli MR and Arcangeli A: Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol 2012: 868645, 2012.
50. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
51. Badescu A, Georgescu CV, Vere CC, Craitoiu S and Grigore D: Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. Rom J Morphol Embryol 53: 997-1005, 2012.
52. Letícia Trivellato Gresta IARJaMMDÁC: Microvessel density quantification in gastric cancer: comparing methods for standard measures. J Cancer Sci Ther 6: 401-405, 2014.
53. Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H and Mori K: Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC cancer 12: 37, 2012.
54. Li WB, Zuo XL, Li CQ, Zuo F, Gu XM, Yu T, Chu CL, Zhang TG and Li YQ: Diagnostic value of confocal laser endomicroscopy for gastric superficial cancerous lesions. Gut 60: 299-306, 2011.
55. Kuznetsov K, Lambert R and Rey JF: Narrow-band imaging: potential and limitations. Endoscopy 38: 76-81, 2006.
56. Committee AT, Song LM, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, Kethu SR, Kwon RS, Mamula P, Pedrosa MC, Rodriguez SA and Tierney WM: Autofluorescence imaging. Gastrointestinal Endoscopy 73: 647-650, 2011.
57. Nishimura J, Nishikawa J, Nakamura M, Goto A, Hamabe K, Hashimoto S, Okamoto T, Suenaga M, Fujita Y, Hamamoto Y and Sakaida I: Efficacy of i-Scan Imaging for the detection and diagnosis of early gastric carcinomas. Gastroenterol Res Pract 2014: 819395, 2014.
58. Cannizzaro R, Mongiat M, Canzonieri V, Fornasarig M, Maiero S, De Re V, Todaro F, De Paoli P and Spessotto P: Endomicroscopy and cancer: a new approach to the visualization of neoangiogenesis. Gastroenterol Res Pract 2012: 537170, 2012.
59. Gheonea Di, Cartana T, Ciurea T, Popescu C, Badarau A and Saftoiu A: Confocal laser endomicroscopy and immunoendoscopy for real-time assessment of vascularization in gastrointestinal malignancies. World J Gastroenterol 17: 21-27, 2011.
60. Foersch S, Kiesslich R, Waldner MJ, Delaney P, Galle PR, Neurath MF and Goetz M: Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. Gut 59: 1046-1055, 2010.
61. Buchner AM, Gomez V, Heckman MG, Shahid MW, Achem S, Gill KR, Jamil LH, Kahaleh M, Lo SK, Picco M, Riegert-Johnson D, Raimondo M, Sciemeca D, Wolfsen H, Woodward T and Wallace MB: The learning curve of in vivo probe-based confocal laser endomicroscopy for prediction of colorectal neoplasia. Gastrointest Endosc 73: 556-560, 2011.
62. Jun BY, Lim CH, Lee WH, Kim JS, Park JM, Lee IS, Kim SW and Choi MG: Detection of neoplastic gastric lesions using capsule endoscopy: pilot study. Gastroenterol Res Pract 2013: 730261, 2013.
63. Vilarino F, Spyridonos P, Deiorio F, Vitria J, Azpiroz F and Radeva P: Intestinal motility assessment with video capsule endoscopy: automatic annotation of phasic intestinal contractions. IEEE Trans Med Imaging 29: 246-259, 2010.
64. Liao Y, Yang ZL, Peng JS, Xiang J and Wang JP: Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol 28: 777-782, 2013.